Cargando…

Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter

This case is the first document to describe a patient receiving anti-programmed cell death 1 (PD-1) antibodies which showed cranial dura matter involvement. According to the increasing use of anti-PD-1 monoclonal antibodies, adverse effects can occur in several organs since its ligand PD-L1 and PD-L...

Descripción completa

Detalles Bibliográficos
Autores principales: Kataoka, Hiroshi, Shimada, Daisuke, Nanaura, Hitoki, Sugie, Kazuma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436277/
https://www.ncbi.nlm.nih.gov/pubmed/34527250
http://dx.doi.org/10.1093/omcr/omab077
_version_ 1783751967229607936
author Kataoka, Hiroshi
Shimada, Daisuke
Nanaura, Hitoki
Sugie, Kazuma
author_facet Kataoka, Hiroshi
Shimada, Daisuke
Nanaura, Hitoki
Sugie, Kazuma
author_sort Kataoka, Hiroshi
collection PubMed
description This case is the first document to describe a patient receiving anti-programmed cell death 1 (PD-1) antibodies which showed cranial dura matter involvement. According to the increasing use of anti-PD-1 monoclonal antibodies, adverse effects can occur in several organs since its ligand PD-L1 and PD-L2 are expressed in a wide variety of tissues. The estimated rate of neurological complications is 1–4.2% of patients, and neuromuscular disorders are the most common. Adverse effects on the central nervous system including encephalitis are less frequent. Here, a patient receiving anti-PD-1 antibodies showed cranial dura matter involvement, and the dura enhancement on MRI was resolved by withdrawal of the treatment with anti-PD-1 antibodies only.
format Online
Article
Text
id pubmed-8436277
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-84362772021-09-14 Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter Kataoka, Hiroshi Shimada, Daisuke Nanaura, Hitoki Sugie, Kazuma Oxf Med Case Reports Case Report This case is the first document to describe a patient receiving anti-programmed cell death 1 (PD-1) antibodies which showed cranial dura matter involvement. According to the increasing use of anti-PD-1 monoclonal antibodies, adverse effects can occur in several organs since its ligand PD-L1 and PD-L2 are expressed in a wide variety of tissues. The estimated rate of neurological complications is 1–4.2% of patients, and neuromuscular disorders are the most common. Adverse effects on the central nervous system including encephalitis are less frequent. Here, a patient receiving anti-PD-1 antibodies showed cranial dura matter involvement, and the dura enhancement on MRI was resolved by withdrawal of the treatment with anti-PD-1 antibodies only. Oxford University Press 2021-09-13 /pmc/articles/PMC8436277/ /pubmed/34527250 http://dx.doi.org/10.1093/omcr/omab077 Text en © The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Case Report
Kataoka, Hiroshi
Shimada, Daisuke
Nanaura, Hitoki
Sugie, Kazuma
Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
title Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
title_full Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
title_fullStr Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
title_full_unstemmed Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
title_short Anti-programmed cell death-1 (PD-1) monoclonal antibodies involve reversible cranial dura matter
title_sort anti-programmed cell death-1 (pd-1) monoclonal antibodies involve reversible cranial dura matter
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436277/
https://www.ncbi.nlm.nih.gov/pubmed/34527250
http://dx.doi.org/10.1093/omcr/omab077
work_keys_str_mv AT kataokahiroshi antiprogrammedcelldeath1pd1monoclonalantibodiesinvolvereversiblecranialduramatter
AT shimadadaisuke antiprogrammedcelldeath1pd1monoclonalantibodiesinvolvereversiblecranialduramatter
AT nanaurahitoki antiprogrammedcelldeath1pd1monoclonalantibodiesinvolvereversiblecranialduramatter
AT sugiekazuma antiprogrammedcelldeath1pd1monoclonalantibodiesinvolvereversiblecranialduramatter